Incidentally detected asymptomatic hepatitis C virus infection with significant fibrosis: Possible impacts on management

Gupta, Rakesh Kumar; Sakhuja, Puja; Majumdar, Kaushik; Ali, Shahajad; Srivastava, Siddharth; Sachdeva, Sanjeev; Sharma, Barjesh C.; Puri, Amarender Singh

doi:10.4103/ijpm.ijpm_240_17

Cited by 4 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it was correlated with HAI score in the study of Zechini B et al (18), HCV-RNA was not correlated with fibrosis score. Also similarly to our study results, Gupta et al (15) revealed that HCV-RNA showed no correlation with both HAI and fibrosis. In summary, we believe that HCV-RNA should not be considered as a good indicator of liver fibrosis.…”

Section: Alt (U/l) Ast (U/l) Ast/altsupporting

confidence: 91%

“…Similarly to our results, Shahid et al (13) showed that AST and ALT significantly correlated with the stages of fibrosis. However, there are some studies in literature which demonstrates that AST was better than ALT as a marker of the progression of liver damage, or that both transaminases showed no correlation with fibrosis (11,14,15,16,17,18).…”

Section: Alt (U/l) Ast (U/l) Ast/altmentioning

confidence: 99%

See 1 more Smart Citation

Are Liver Transaminases and Hepatitis C Virus-RNA Viral Loads Reliable Markers for Estimating Liver Fibrosis in Patients Recently Diagnosed with Hepatitis C? Evaluation of the Data of Ninety-five Young and Middle-aged Males in a Genotype-1b Prevalent Country

Yeni̇lmez¹,

Çeti̇nkaya²

2019

vhd

View full text Add to dashboard Cite

Amaç: Karaciğer biyopsisi invaziv bir yöntem olmakla birlikte hala karaciğer hastalıklarının ciddiyetini belirlemek için altın standart yöntem olarak kabul edilir. Gereç ve Yöntemler: Bu retrospektif çalışmaya toplam 95 genç ve orta yaşlı erkek hasta dahil edildi. Patolojik değerlendirme için ISHAK skorlama sistemi kullanıldı. Fibrozisin evrelerinin öngörülmesinde alanin aminotransferaz (ALT), aspartat aminotransferaz (AST), AST/ ALT oranı ile HCV-RNA ve histolojik aktivite indeksi (HAİ) skorları arasındaki ilişkiler araştırıldı. Bulgular: F3'ü öngörmede, >35 yaşın [olasılık oranı (OR): 3.56; %95 güven aralığı (Cl): 1.24-10.24; p=0,021] önemli bir risk faktörü olduğu gösterildi. F ≥2 için, 40 IU/mL'nin üzerindeki ALT ve AST değerlerinin önemli risk faktörleri olduğu ortaya kondu (sırasıyla OR: 2,97; %95 Cl: 1,09-8,06; p=0,03 ve OR: 2,88; %95 Cl: 1,17-7,09; p=0,020). HAİ dışındaki tüm indirek fibroz göstergeleri, hem F ≥2 hem de F ≥3'ü (AUC 0,50 ila 0,68) öngörmede düşük/orta dereceli tanısal doğruluk gösterdi. Alıcı işletim karakteristiği (ROC) analiz sonuçlarına göre, ALT, AST, AST/ALT oranı, Log10 HCV-RNA ve HAİ için F ≥3'ü öngörmedeki optimum kesme değerleri sırasıyla 94 U/L, 55U/L,

show abstract

Section: Alt (U/l) Ast (U/l) Ast/altsupporting

confidence: 91%

Section: Alt (U/l) Ast (U/l) Ast/altmentioning

confidence: 99%

Are Liver Transaminases and Hepatitis C Virus-RNA Viral Loads Reliable Markers for Estimating Liver Fibrosis in Patients Recently Diagnosed with Hepatitis C? Evaluation of the Data of Ninety-five Young and Middle-aged Males in a Genotype-1b Prevalent Country

Yeni̇lmez¹,

Çeti̇nkaya²

2019

vhd

View full text Add to dashboard Cite

show abstract

Safety and Efficacy of Direct Antiviral Agents for Hepatitis C in Patients with Malignancies Other Than Liver Cancer: A Case Series

et al. 2022

View full text Add to dashboard Cite

(1) Background: direct-acting antivirals (DAA) are the current standard of care for chronic hepatitis C. Oncologic patients remain among the most difficult-to-treat subgroups of hepatitis C virus (HCV)-infected patients due to their clinical frailty and complex therapeutic protocols received. (2) Methods: we retrospectively collected and analysed clinical data of 30 consecutive patients treated with DAA, between 2015 and 2022, for chronic HCV infection in the context of oncologic disease. (3) Results: most patients were females (63.3%), median age was 67 years, HCV genotype 1 was prevalent (60%), and median HCV RNA levels were 2.2 × 106 IU/mL. The most common malignancy was breast cancer (37%), and the chief oncologic drugs co-administered with DAAs were platinum derivatives, paclitaxel, cyclophosphamide, taxol, pembrolizumab, rituximab, imatinib, enantone and tamoxifen. Overall, 50% of patients had chronic hepatitis. A total of 76.7% underwent a sofosbuvir-based treatment. Sustained virological response 12 weeks after the end of therapy (SVR12) was reached in all patients. After SVR12, two patients died. DAA treatment was well tolerated; no patients had to stop DAA treatment or showed any adverse event or drug-drug interaction specifically attributable to DAAs. (4) Conclusions: DAA treatment should be promptly offered to oncologic patients with chronic hepatitis C in order to achieve aminotransferase normalization and viremia control, making antineoplastic therapy feasible and safe.

show abstract

Mathematical Model of the Role of Asymptomatic Infection in Outbreaks of Some Emerging Pathogens

2020

View full text Add to dashboard Cite

Preparation for outbreaks of emerging infectious diseases is often predicated on beliefs that we will be able to understand the epidemiological nature of an outbreak early into its inception. However, since many rare emerging diseases exhibit different epidemiological behaviors from outbreak to outbreak, early and accurate estimation of the epidemiological situation may not be straightforward in all cases. Previous studies have proposed considering the role of active asymptomatic infections co-emerging and co-circulating as part of the process of emergence of a novel pathogen. Thus far, consideration of the role of asymptomatic infections in emerging disease dynamics have usually avoided considering some important sets of influences. In this paper, we present and analyze a mathematical model to explore the hypothetical scenario that some (re)emerging diseases may actually be able to maintain stable, endemic circulation successfully in an entirely asymptomatic state. We argue that an understanding of this potential mechanism for diversity in observed epidemiological dynamics may be of considerable importance in understanding and preparing for outbreaks of novel and/or emerging diseases.

show abstract

Incidentally detected asymptomatic hepatitis C virus infection with significant fibrosis: Possible impacts on management

Abstract: Serum transaminases and HCV RNA titers are poor predictors of disease severity and fibrosis. Since HCV shows a slow disease progression, higher stage may predict a worse prognosis irrespective of the low viral RNA load. Liver biopsy may help guide therapeutic decisions in IDHCV infection.

Cited by 4 publications

References 19 publications

Are Liver Transaminases and Hepatitis C Virus-RNA Viral Loads Reliable Markers for Estimating Liver Fibrosis in Patients Recently Diagnosed with Hepatitis C? Evaluation of the Data of Ninety-five Young and Middle-aged Males in a Genotype-1b Prevalent Country

Are Liver Transaminases and Hepatitis C Virus-RNA Viral Loads Reliable Markers for Estimating Liver Fibrosis in Patients Recently Diagnosed with Hepatitis C? Evaluation of the Data of Ninety-five Young and Middle-aged Males in a Genotype-1b Prevalent Country

Safety and Efficacy of Direct Antiviral Agents for Hepatitis C in Patients with Malignancies Other Than Liver Cancer: A Case Series

Mathematical Model of the Role of Asymptomatic Infection in Outbreaks of Some Emerging Pathogens

Contact Info

Product

Resources

About